Health Condition 1: N952- Postmenopausal atrophic vaginitis
Conditions
Interventions
Intervention1: Platelet Rich Plasma: Injection given every 3 weeks for 4 times Into the anterior vaginal wall using 26-G needles
Control Intervention1: conjugated estradiol vaginal cream: They have wi
Sponsors
Indian Council of Medical Research
JNMC WARDHA
Eligibility
Inclusion criteria
Inclusion criteria: 1.postmenopausal women with VHI 2.All eligible women giving informed written consent
Exclusion criteria
Exclusion criteria: 1.Women who Had any contraindication for estrogen therapy will be excluded from the study. 2.Women with VHI >=25 3.Women with any history of carcinoma of the breast or endometrium 4.Women with abnormal genital bleeding, acute thrombophlebitis, or thromboembolic disorders associated with previous estrogen use. 5.Women with current Genito urinary infection 6.Women who underwent hormone replacement therapy, treated with systemic or vaginal estrogen within 6 months prior to the study,
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) improvement in Vaginal Health Index (VHI). 2) improvement in Vulvovaginal atrophy (VVA) symptoms using the Visual analog scale (VAS). Timepoint: 1) baseline 2) 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of tolerability and safety of Platelet rich plasma (PRP)Timepoint: 12 weeks | — |
Countries
India
Contacts
Public ContactDr Tejal Waghe
DATTA MEGHE INSTITUTE OF HIGHER EDUCATION AND RESEARCH
Outcome results
None listed